118 related articles for article (PubMed ID: 33415928)
1. Treatment of Corticosteroid Non-responsive Relapse of Neuromyelitis Optica with Intravenous Gamma Globulin - a Case Report.
Dimitrova M; Iliev D
Folia Med (Plovdiv); 2020 Dec; 62(4):861-865. PubMed ID: 33415928
[TBL] [Abstract][Full Text] [Related]
2. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.
Elsone L; Panicker J; Mutch K; Boggild M; Appleton R; Jacob A
Mult Scler; 2014 Apr; 20(4):501-4. PubMed ID: 23986097
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
Viswanathan S; Wong AH; Quek AM; Yuki N
J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders.
Tanaka M; Kinoshita M; Tanaka K
Mult Scler; 2015 Apr; 21(5):669. PubMed ID: 25662352
[No Abstract] [Full Text] [Related]
6. [Treatment of neuromyelitis optica].
Nomura K
Nihon Rinsho; 2013 May; 71(5):829-38. PubMed ID: 23777090
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders with vertigo as the initial symptom: A case report.
Guo Q; Han D; Liu J; He K; Ma R
Medicine (Baltimore); 2019 Aug; 98(34):e16906. PubMed ID: 31441871
[TBL] [Abstract][Full Text] [Related]
8. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
9. Overlapping demyelinating syndrome (Neuromyelitis optica spectrum disorders NMOSD with anti-NMDA receptor encephalitis); A case report.
Sinani AA; Maawali SA; Alshekaili J; Kindi MA; Ramadhani KA; Khabouri JA; Nadeem A; Salti AA
Mult Scler Relat Disord; 2020 Jul; 42():102153. PubMed ID: 32413838
[TBL] [Abstract][Full Text] [Related]
10. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).
Bakker J; Metz L
Can J Neurol Sci; 2004 May; 31(2):265-7. PubMed ID: 15198456
[TBL] [Abstract][Full Text] [Related]
11. Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin.
Bichuetti DB; de Oliveira EM
J Clin Immunol; 2013 Feb; 33(2):307. PubMed ID: 23054342
[No Abstract] [Full Text] [Related]
12. "Response to the commentary on "neuromyelitis optica: potential roles for intravenous immunoglobulin"".
Wingerchuk DM
J Clin Immunol; 2013 Feb; 33(2):308. PubMed ID: 23054343
[No Abstract] [Full Text] [Related]
13. Neuromyelitis optica with brain stem involvement in a middle-aged Ethiopian woman: a case report and review of literature.
Kassu RA; Mulatu HA; Gizaw S; Fisseha H; Musema A; Keder A; Negash S; Tefera F; Lissanwerk A; Tamrat L
J Med Case Rep; 2021 Oct; 15(1):489. PubMed ID: 34598735
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
16. Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Dai Y; Lu T; Wang Y; Fang L; Li R; Kermode AG; Qiu W
J Clin Neurosci; 2016 Apr; 26():168-70. PubMed ID: 26704780
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
18. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
19. Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica.
Wingerchuk DM; Weinshenker BG
Continuum (Minneap Minn); 2013 Aug; 19(4 Multiple Sclerosis):944-67. PubMed ID: 23917095
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
